Antibodies against trim9 and/or trim67 in paraneoplastic neurological syndromes
AssigneesHospices Civils De Lyon, Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique (CNRS), Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsLe Duy DO, Jérôme HONNORAT, Véronique ROGEMOND
Life of this patent
Estimating the term…
Abstract
The invention relates to a process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.
Claims20
Process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.
Process in vitro for identifying the presence of a tumor in an individual affected by a neurological syndrome, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.
Process for monitoring the evolution of a PNS in an individual affected by this syndrome, comprising:
- a. Determining the amount of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual, at a moment T0;
- b. Determining the amount of the same at least one antibody as quantified in step (a), in a biological fluid of said individual, at a moment T1 later than T0;
- c. Comparing the two amounts obtained at T0 and
- wherein a decrease, between T0 and T1, of the amount of said at least one antibody, is indicative of an improvement in the PNS affecting the individual.
Dependencies are inferred from the claim text.